ANTERIS TECHNOLOGIES GLOBAL CORP (AVR)
Health Care · Transcatheter Heart Valve Replacement Devices · NASDAQ
A pre-revenue structural heart company pioneering a biomimetic, single-piece aortic valve designed to replicate healthy valve hemodynamics and durability in TAVR-eligible patients with aortic stenosis.
What ANTERIS TECHNOLOGIES GLOBAL CORP does
Anteris Technologies Global Corp is a structural heart company developing transcatheter aortic valve replacement (TAVR) therapies for aortic stenosis. The company's lead product, the DurAVR® THV System, is a single-piece biomimetic valve utilizing proprietary ADAPT® tissue-enhancing technology designed to mimic the performance of a healthy human aortic valve and deployed via the ComASUR® Delivery System. As of December 2025, over 130 patients have received DurAVR® implants, with the company conducting the PARADIGM Trial, a pivotal randomized controlled study comparing DurAVR® against commercially available TAVR alternatives.
Themes: ["Transcatheter aortic valve replacement (TAVR)","Structural heart disease","Aortic stenosis treatment","Minimally-invasive cardiac interventions","Biomimetic medical devices","Tissue-engineered heart valves"]
Fundamentals
- Price$9.49 as of 2026-07-09 close
- Market cap$945M as of 2026-07-10
- 1-year return+177.0% as of 2026-07-09 close
- Net margin-5148.8% as of 2026-07-10
- Gross margin+74.3% as of 2026-07-10
- ROE-64.7% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-0.5% as of 2026-07-10
- Beta2.00 as of 2026-07-10
Key risks (from latest filing)
["Clinical and regulatory risk: the company is unprofitable and dependent on successful completion of the PARADIGM pivotal trial; failure to achieve primary endpoints could delay or prevent FDA approval and commercialization","Competitive market risk: established TAVR players (Edwards Lifesciences, Medtronic) and emerging competitors dominate the market; DurAVR® has limited clinical data and only 130 patients implanted to date versus thousands for competitors","Capital requirement risk: with minimal net sales ($494K in Q1 2026) and negative net margins, the company requires ongoing funding to support R&D and clinical trials; inability to raise capital could impair operations"]
Competitors & peers
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.